LEADER 04340nam 22006015 450 001 9910300207303321 005 20200629143230.0 010 $a3-319-12505-2 024 7 $a10.1007/978-3-319-12505-3 035 $a(CKB)3710000000342467 035 $a(EBL)1967927 035 $a(SSID)ssj0001424493 035 $a(PQKBManifestationID)11832255 035 $a(PQKBTitleCode)TC0001424493 035 $a(PQKBWorkID)11369588 035 $a(PQKB)10297420 035 $a(DE-He213)978-3-319-12505-3 035 $a(MiAaPQ)EBC1967927 035 $a(PPN)183520831 035 $a(EXLCZ)993710000000342467 100 $a20150116d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aHodgkin Lymphoma $eA Comprehensive Overview /$fedited by Andreas Engert, Anas Younes 205 $a2nd ed. 2015. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015. 215 $a1 online resource (439 p.) 225 1 $aHematologic Malignancies,$x2197-9766 300 $aDescription based upon print version of record. 311 $a3-319-12504-4 327 $aPart I: From Hodgkin?s disease to Hodgkin Lymphoma: Epidemiology -- The role of viruses in the genesis of Hodgkin Lymphoma -- Pathology and molecular pathology of Hodgkin Lymphoma -- Microenvironment, cross-talk and immune escape mechanisms -- What will we learn from Genomics and Proteomics in Hodgkin Lymphoma? Part II: Diagnosis and treatment:Clinical evaluation -- Functional imaging -- Prognostic factors -- Principles of radiation techniques in Hodgkin Lymphoma -- Principles of chemotherapy in Hodgkin Lymphoma -- Treatment of early favorable Hodgkin Lymphoma -- Treatment of early unfavorable Hodgkin Lymphoma -- Treatment of advanced-stage Hodgkin Lymphoma -- Relapsed and refractory Hodgkin Lymphoma -- Paediatric Hodgkin Lymphoma. Part III: Special Clinical Situations: Lymphocyte-predominant Hodgkin Lymphoma -- The management of Hodgkin Lymphoma during pregnancy -- The management of HIV-Hodgkin Lymphoma -- The management of elderly patients with Hodgkin Lymphoma -- Allogeneic transplantation for relapsed of Hodgkin Lymphoma -- Targeting CD 30 -- Other new agents for patients with Hodgkin Lymphoma. Part IV: Survivorship: Quality of Life in Hodgkin Lymphoma -- Second malignancy risk after treatment of Hodgkin Lymphoma -- Cardiovascular and pulmonary late effects -- Gonadal dysfunction and fertility preservation  in Hodgkin Lymphoma patients. 330 $aThis book examines in detail the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the management appropriate in special clinical circumstances, including in the elderly, pregnant women, and those with lymphocyte-predominant disease. Careful attention is devoted to the emerging individually tailored treatment strategies that are especially appealing given their potential to reduce early and late treatment side effects in this generally young patient population. In addition, clear guidance is provided on the management of Hodgkin survivors. Other topics addressed include epidemiology, pathogenesis, the role of the microenvironment, initial clinical evaluation, imaging diagnosis, use of staging systems, and prognostic factors. The second edition of Hodgkin Lymphoma: A Comprehensive Overview has been revised and updated by the key opinion leaders to reflect recent progress in the field. It will be of great value to hematologists, oncologists, and all others with an interest in Hodgkin lymphoma. . 410 0$aHematologic Malignancies,$x2197-9766 606 $aHematology 606 $aOncology 606 $aHematology$3https://scigraph.springernature.com/ontologies/product-market-codes/H3307X 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 615 0$aHematology. 615 0$aOncology. 615 14$aHematology. 615 24$aOncology. 676 $a610 676 $a616.15 676 $a616994 702 $aEngert$b Andreas$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aYounes$b Anas$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910300207303321 996 $aHodgkin Lymphoma$91763320 997 $aUNINA